Traws Pharma, Inc. (TRAW)

0.6410 -0.0016 (-0.25%) As of 10:27AM EDT. Market open.

Traws Pharma, Inc.

12 Penns Trail
Newtown, PA 18940
United States
267 759 3680
https://www.trawspharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 17

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Steven M. Fruchtman M.D.	President & Chief Scientific Officer of Oncology	919.13k	N/A	1951
Mr. Mark Patrick Guerin CPA	Chief Financial Officer	676.29k	N/A	1969
Dr. Victor Moyo M.D.	Chief Medical Officer of Oncology	326.64k	N/A	N/A
Dr. Iain D. Dukes DPHIL, M.A., Ph.D.	Executive Chairman	N/A	N/A	1958
Dr. Werner Cautreels Ph.D.	CEO & Director	N/A	N/A	1952
Dr. Nikolay Savchuk Ph.D.	COO & Director	N/A	N/A	1969
Robert Redfield M.D.	Acting Chief Medical Officer	N/A	N/A	N/A
Dr. Charles David Pauza Ph.D.	Chief Scientific Officer of Virology	N/A	N/A	1954

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Corporate governance

Traws Pharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.